Dr. Rozencweig joined Innate Pharma in 2009. He is recognized as a world leading expert and opinion leader in medical oncology and anti-cancer drug development. He built and led the clinical research group at Bristol-Myers Squibb (“BMS”) that developed all the NCEs brought by BMS to the market from 1983 to 2001 in the area of cancer (including carboplatin and paclitaxel).
Under his leadership, a total of 17 marketing applications (NDAs or sNDAs1) were successfully filed by BMS in the area of cancer, HIV and infectious diseases.
Before joining the industry, Dr. Rozencweig pursued an academic career and currently serves as an Adjunct Associate Professor of Medicine at New York University, NY. He created and chaired a number of European groups (EORTC) devoted to multinational drug-oriented and disease-oriented trials (e.g., Early Clinical Trials Group).
Dr. Rozencweig is a medical doctor. He graduated from the Université Libre de Bruxelles, in Belgium.